Development of a nomogram for predicting liver transplantation prognosis in hepatocellular carcinoma

Table 1 Characteristics of hepatocellular carcinoma patients, n (%)

Variables	Value
Gender (male/female)	147 (91.9)/13 (8.1)
Age, yr (≤ 50/> 50)	69 (43.1)/91 (56.9)
OS status (survive/dead)	105 (65.5)/55 (34.5)
RFS status (survive/relapsed)	104 (65.0)/56 (35.0)
ALT, U/L (≤ 40/> 40)	91 (56.9)/69 (43.1)
AST, U/L (≤ 40/> 40)	61 (38.1)/99 (61.9)
ALP, U/L (≤ 125/> 125)	108 (67.5)/52 (32.5)
GGT, U/L (≤ 60/> 60)	55 (34.4)/105 (65.6)
AFP, ng/mL (≤ 200/200-1000/> 1000)	107 (66.9)/19 (11.8)/34 (21.3)
GP73, ng/mL (≤ 150/> 150)	84 (52.5)/76 (47.5)
DCP, ng/mL (≤ 40/> 40)	96 (60.0)/64 (40.0)
CK18-M65, U/L (≤ 500/> 500)	48 (30.0)/112 (70.0)
CK18-M30, U/L (≤ 500/> 500)	91 (56.9)/69 (43.1)
Pathological diferentiation (well/moderate/poor)	9 (5.6)/127 (79.4)/24 (15.0)
Number of tumours (solitary/multiple)	79 (49.4)/81 (50.6)
Maximum tumor diameter, cm (≤ 5/> 5)	112 (70.0)/48 (30.0)
Total tumor diameter, cm (≤ 8/> 8)	114 (71.3)/46 (28.7)
Vascular invasion (yes/no)	42 (26.2)/118 (73.8)
Lymph node metastasis (yes/no)	20 (12.5)/140 (87.5)
Membrane invasion (yes/no)	51 (31.9)/109 (68.1)
Microsatellite lesions (yes/no)	79 (49.4)/81 (50.6)
Child-Pugh score (≤ 8/> 8)	116 (71.5)/44 (27.5)
MELD score (≤ 20/> 20)	147 (91.9)/13 (8.1)
Milan (yes/no)	64 (40.0)/96 (60.0)
UCSF (yes/no)	77 (48.1)/83 (51.9)
Hangzhou (yes/no)	109 (68.1)/51 (31.9)

DCP: Des-gamma-carboxy prothrombin; ALT: Alanine transaminase; AST: Aspartate transaminase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; DCP: Des-gamma-carboxy prothrombin; GP73: Golgi protein 73; OS: Overall survival; RFS: Recurrence free survival.